Affini-T

Affini-T is a precision immunotherapy company focused on developing potentially curative treatments for patients with solid tumors by targeting core oncogenic driver mutations. The companys expertise lies in pinpointing highly active TCRs T-cell receptors directed at crucial tumor biology elements such as KRAs Kirsten rat sarcoma viral oncogene homolog and p53. Through the integration of synthetic biology and gene editing technologies, Affini-T aims to overcome the challenges of the immunosuppressive tumor microenvironment, fostering a sustained anti-tumoral response. This innovative approach holds promise in revolutionizing therapies for pancreatic, colorectal, and lung cancers.